Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
177
resultados
Última actualización
04/05/2025 [07:05:00]
Resultados 125 a 150 de 177
Resumen de: AU2023333282A1
This disclosure concerns amplification primers, hybridization assay probes, compositions containing such primers and probes, and associated reagents, kits, and methods, that can be used to analyze samples for the presence of SARS-CoV-2, Influenza A virus, Influenza B virus, Respiratory Syncytial Virus A, and/or Respiratory Syncytial Virus B target nucleic acids.
Resumen de: AU2023329395A1
The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.
Resumen de: AU2023326053A1
Described herein are methods and related compositions for determining the likelihood of neurological post-acute sequelae of COVID-19 (NP ASC) in a subject based on the levels of biomarkers in a combination of biomarkers from a biological sample from the subject. Also disclosed herein are methods for treating a subject identified as having a high likelihood of suffering from NP ASC and treating the subject by modulating the level or activity of an NPASC therapeutic target identified herein.
Resumen de: WO2025059202A1
Disclosed are methods for detecting if a biological sample (e.g., serum, blood, plasma) contains antibodies against SARS-CoV-2 S glycoproteins comprising: (i) providing a surface coated with a SARS-CoV-2 S glycoprotein; (ii) exposing the surface to the biological sample; (iii) exposing the surface to a secondary antibody; and (iv) detecting the secondary antibody that is bound to the surface; wherein the biological sample contains antibodies that bind to the SARS-CoV-2 S glycoprotein if secondary antibody is detected.
Resumen de: ES3007932A1
5-Fluorouracil (5-FU) for use as an antiviral, alone or in combination with peptides that inhibit the binding between nsp10-nsp14, and nsp10-nsp16, against viruses of the Coronaviridae family, preferably SARS S-CoV-2. (Machine-translation by Google Translate, not legally binding)
Resumen de: WO2025059470A1
Provided herein are engineered protein comprising stabilized coronavirus S protein ectodomains, such as stabilized SARS-CoV-2 S2 domain-only ectodomains that exhibit improved conformational homogeneity and biophysical stability. The ectodomains are incorporated into nanoparticles. Methods are also provided for use of the stabilized coronavirus S protein ectodomains and/or nanoparticles as diagnostics, in screening platforms, and/or in vaccine compositions.
Resumen de: WO2025055944A1
Provided are treatment and prevention of hepatitis B. In particular, provided is a method for treating or preventing hepatitis B in a subject, the method comprises: administering effective amount of COVID-19 vaccine to the subject. Further provided is use of COVID-19 vaccine in manufacturing a drug for treating or preventing hepatitis B.
Resumen de: WO2025054715A1
Here we describe a two-pronged localized nanomaterial-based approach for limiting SARS-CoV-2 infection in nasal and upper airway epithelial cells that involves lipid nanoparticles (LNPs) that act as receptor decoys to bind viral spike protein (LNP-trap) and LNPs to delivery siRNA to host cells to knock down the viral entry targets (LNP-trim). The LNP-trap formulations consisted of cell- impermeable lipid nanoparticles surface modified with ACE2 peptide, recombinant ACE2 or SARS- CoV-2 spike mAb that can bind to SARS-CoV-2 and potentially neutralize them. The LNP-trim LNP formulations were cell-permeable and capable of delivering siRNA for reducing ACE2 and TMPRSS2 expression in host cells. The in vitro studies demonstrated that both the LNP-trap and LNP-trim formulations were safe and effective at inhibiting virus-host cell interactions and reducing viral infection. Initial assessment of the LNP-trap and LNP-trim LNPs following nasal administration in mice confirmed nasal retention and biocompatibility.
Resumen de: US2025090572A1
The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via competitive binding to SARS-CoV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-CoV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μM, and low cytotoxicity, making it promising for clinical use. While established SARS-CoV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.
Resumen de: US2025090557A1
Disclosed herein are methods of using one or more mitochondrial targeted antioxidants, such as mitoquinol or mitoquinone, to prevent, inhibit, and/or treat infections and symptoms caused by infection by a coronavirus, such as SARS-CoV-2.
Resumen de: US2025090568A1
A method of treating or preventing Alzheimer's disease or related dementias in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Brain gene expression profiles of severe COVID-19 patients show increased expression of several innate immune response genes and genes implicated in Alzheimer's disease pathogenesis. The gene expression signature includes genes involved in inflammation, protein folding/trafficking, complement activation, calcium homeostasis, and amyloid/tau processing. The gene expression signature is correlated with tau pathology, α-synuclein, and demyelination with neuroinflammation being increased in old versus young CoV-2 infected mice.
Resumen de: US2025089707A1
An eco-friendly quarantine composition has a function of killing phospholipid enveloped viruses, The eco-friendly quarantine composition includes: 10 to 40 wt. % of polyoxyethylene lauryl ether, 0.01 to 10 wt. % of polyoxyethylene 2-ethylhexyl ether, 0.01 to 10 wt. % of polyoxyethylene polyoxypropylene alkyl ether, and a balance of solvent, based on the total 100 wt. % of the composition. The eco-friendly quarantine composition may have 100% of SARS-CoV-2 virus removal rate in 1 minute and an effect of killing 100% of highly pathogenic avian influenza virus in 1 to 10 minutes. The composition has low cytotoxicity such that IC50 value (%) for human epithelial keratinocyte cells (HaCaT), human bronchial epithelial cells (BEAS-2B), and human monocyte cells (THP-1) is in a range of 0.003 to 0.0045, and effects of having antibacterial activity against non-pathogenic strains, and pathogenic strains.
Resumen de: AU2022471272A1
A system for cargo transport in the field of intermodal logistics aims to solve supply chain-related disruptions experienced during the Covid-19 pandemic. Cargo frame cargo ships (24), cargo frame barges (26), cargo frame docks (20), 3-axis structures, and 3-axis hoists (10) utilize a cargo frame to bundle series 1 freight containers, vehicles, dry-bulk, wet-bulk, and other general cargoes in a stackable, modular manner. Purpose-built 3-axis structures increase the footprint of ports where cargo frames are stacked, stored, and retrieved. Semi-truck queueing towers (22), and freight car transshipment yards (34) allow for timely coordination of cargo transfer at a multi-level port (48), increasing the throughput of intermodal cargoes.
Resumen de: WO2025054468A1
Electrocardiography (ECG) data acquired from a subject and processed with a machine learning model to determine whether the subject has, or is developing, an influenza infection. The machine learning model generates classified feature data that are indicative of the presence and/or likelihood of an influenza infection. Scalogram and/or spectrogram data may be generated from the ECG data and processed with a machine learning model to determine whether the subject has, or is developing, a respiratory infection, such as an influenza or COVID-19 infection. The machine learning model generates classified feature data that are indicative of the presence and/or likelihood of a respiratory infection.
Resumen de: US2025082716A1
Provided are methods for treating subjects with coronavirus infections. The methods include providing a subject infected with a coronavirus resulting in a prothrombotic condition in addition to being infected by a coronavirus, and administering to the subject an angiotensin (1-7) peptide or an analog or derivative thereof, a Mas Receptor (MasR) agonist, or any combination thereof. The subject may be suffering from COVID-19 disease, including but not limited to a thrombotic complication, an adverse pregnancy outcome, and/or a complication resulting from an underlying prothrombotic state. Also provided are compositions that include Ang (1-7) peptides, analogs, and/or derivatives thereof that are associated with degradable and/or non-degradable polymers having electrostatic interactions therewith, hydrophobic interaction therewith, hydrogen bonding interactions therewith, or any combination thereof. Also provided are uses of Ang (1-7) peptides, analogs, and/or derivatives thereof and/or a Mas Receptor (MasR) agonists for treating subjects infected with coronaviruses and/or for preparing medicaments therefore.
Resumen de: US2025082746A1
Provided are circular RNAs (circRNAs) encoding an antigenic polypeptide of a SARS-CoV-2 variant. Provided are circRNA vaccines against a SARS-CoV-2 variant, such as a Delta or Omicron variant. The circRNA vaccine comprises a circRNA comprising a nucleic acid sequence encoding an antigenic polypeptide comprising a Spike(S) protein or a fragment thereof of a SRAS-CoV-2 variant. Also provided are methods of treating or preventing a SARS-CoV-2 infection using the circRNAs or compositions thereof.
Resumen de: US2025082869A1
Disclosed are a nebulization cup and application in nebulized inhalation administration thereof, and especially application in nebulized inhalation administration of a preventive and/or therapeutic drug for a respiratory disease (such as SARS-CoV-2 vaccine). After adding an antistatic agent, the nebulization cup can effectively maintain the stability of drug mist within a certain period of time, with stable particle size, less drug residue in the cup, thus ensuring effective inhalable amount, and the administration operation is simple and convenient, thus the nebulization cup can significantly improve the inoculation efficiency and can be used for large-scale inoculation.
Resumen de: US2025082737A1
The present invention relates to fusion proteins of ACE2 with IgM or IgG2 Fc and the medical use of these fusion proteins, in particular in the prevention or treatment of infections with coronaviruses such as SARS-CoV-2.
Resumen de: US2025082541A1
The present invention provides an acumoxa therapy device utilizing energy waves for preventing, alleviating or treating COVID-19 (SARS-COV-2) coronavirus infection. In one embodiment, the device delivers energy in a non-invasive manner. In one embodiment, the device is configured to include an energy pin and one or more energy rings. In one embodiment, the device delivers sufficient energy to certain body parts such as acupoints to achieve an intervening and/or. therapeutic effect. In one embodiment, the device can maintain or improve general health, or can alleviate or treat a subject with COVID-19 infection and one or more other conditions. In one embodiment, the present invention also discloses a system comprising the device and uses thereof.
Resumen de: US2025085278A1
The systems and methods herein are directed to carboxylated latex beads and biotin-polysterptavidin as a label material for fluorescence lateral flow assay (LFA) for the diagnosis of SARS-Cov-9 with increased sensitivity. The carboxylated latex and biotin-polystreptavidin instantly increases the fluorescence intensity and the resulting signal enhancement significantly increases sensitivity for analyte detection. The LFA can also be used for the detection of SARS-Cov-2 and as rapid testing kit of COVID-19. The LFA kit allows detection of nucleocapsid protein of SARS-Cov-2 as little as 0.1 ng/ml and as a point of care testing of COVID-19.
Resumen de: US2025085282A1
Disclosed are methods for detecting if a biological sample (e.g., serum, blood, plasma) contains antibodies against SARS-CoV-2 S glycoproteins comprising: (i) providing a surface coated with a SARS-CoV-2 S glycoprotein; (ii) exposing the surface to the biological sample; (iii) exposing the surface to a secondary antibody; and (iv) detecting the secondary antibody that is bound to the surface; wherein the biological sample contains antibodies that bind to the SARS-CoV-2 S glycoprotein if secondary antibody is detected.
Resumen de: US2025084128A1
Disclosed herein are cross-linked peptides either alone or conjugated to PEG(n)-cholesterol (or thiocholesterol) moieties useful for interfering with and inhibiting or preventing coronavirus infection (e.g., infection by SARS-CoV-2). Also disclosed are methods of treating and/or preventing a coronavirus infection (e.g., COVID-19.
Resumen de: US2025084091A1
Described herein are compounds and methods for the treatment of coronavirus infection. The compounds can function as an inhibitor of the main protease (Mpro) of coronaviruses. The compounds can include diphenylmethyl piperazine derivatives, diphenylmethyl piperidine derivatives, diphenylmethylidene piperidine derivatives, tricyclo9.4.0.03,8pentadeca-1(11),3(8),4,6,12,14-hexaen derivatives, tricyclo9.4.0.03,8pentadeca-1(11),3(8),4,6,9,12,14-heptaen derivatives, 6,11-dihydrobenzoc1benzoxepin derivatives, 6,11-dihydrobenzoc1benzothiepin derivatives, 5,5-dioxo-6,11-dihydrobenzoc1benzothiepin derivatives, and 6-oxo-5,11-dihydrobenzoc1benzazepin derivatives, as well as pharmaceutically acceptable salts, hydrates, and prodrugs thereof.
Nº publicación: US2025087037A1 13/03/2025
Solicitante:
OPENCLEAR INC [US]
OpenClear, Inc
Resumen de: US2025087037A1
A smartphone and app executed on the smartphone are used for personal pathogen status verifying that allows an entity to control access to an area of congregation (AOC) at one or more points of entry (POE). In one embodiment, the system may be used for the SARS-CoV-2 virus, but may be similarly used for other pathogens.
BOPI
Sede Electrónica
